<DOC>
	<DOCNO>NCT02506959</DOCNO>
	<brief_summary>The goal clinical research study learn combination panobinostat , gemcitabine , busulfan , melphalan stem cell transplant help control MM . The safety combination also study .</brief_summary>
	<brief_title>Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant Patients With Refractory/Relapsed Myeloma</brief_title>
	<detailed_description>Busulfan Test Dose : If agree take part study , receive test dose busulfan vein 60 minute . This low-level test dose busulfan help doctor decide dose busulfan receive study . You likely receive outpatient clinic week hospital . If give outpatient , admitted hospital Day -11 ( 11 day stem cell return body ) test dose give Day -10 . With stem cell transplant , day receive stem cell call minus day ( Days -11 , -10 , ) . The day receive stem cell call Day 0 . The day receive stem cell call plus day ( Days +1 , +2 , ) . On day busulfan test dose , blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test busulfan . PK test measure amount study drug body different time point help study doctor decide dose busulfan study . These blood sample draw dose busulfan 10 time next 11 hour . The PK blood sample repeat first day high-dose busulfan treatment ( Day -8 ) . A temporary heparin lock line place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . If receive busulfan test dose outpatient : On Days -12 , -11 , -10 , receive palifermin vein 30 second day help decrease risk side effect mouth throat . You admitted hospital Day -9 . If receive busulfan test dose inpatient : On Days -14 , -13 , -12 ( 3 day admit hospital ) , receive palifermin vein 30 second day help decrease risk side effect mouth throat . You admitted hospital Day -11 . Study Drug Administration : Beginning Day -9 , swish liquid caphosol glutamine mouth 4 time day , 2 minute time . You swish liquid every day leave hospital . These drug use help decrease risk side effect mouth throat . On Day -9 Day -2 , receive dexamethasone 2 time day vein 10 minute , take panobinostat mouth 1 time day . On Day -8 receive gemcitabine vein 4 hour . On Days -8 , -7 , -6 , -5 , receive busulfan vein 3 hour day . On Day -3 , receive gemcitabine vein 4 hour melphalan vein 30 minute . On Day -2 , receive melphalan vein 30 minute . On Day -1 , rest . On Day 0 , receive stem cell vein 30-60 minute . On Days 0 , +1 , +2 , receive 3 dos palifermin vein 15-30 second . You also give standard drug help decrease risk side effect . You may ask study staff information drug give risk . As part standard care , remain hospital 3-4 week transplant . After , need stay Houston area , continue outpatient checked infection side effect . Study Tests : Before start study treatment , bone marrow biopsy aspiration check status disease . To collect bone marrow biopsy aspirate , area hip site numb anesthetic , small amount bone bone marrow withdrawn large needle . Length Treatment : The study treatment period Day -12 Day +2 , follow-up described . You may take study early disease get bad , intolerable side effect occur , unable follow study direction . If reason want leave study early , must talk study doctor . It may life-threatening leave study start receive study drug receive stem cell transplant . This blood cell count dangerously low . Follow-Up : About 1 month , 100 day , 6 month , 1 year , every 3-6 month least 2 year transplant long doctor think need : - You physical exam . - Blood ( 4 tablespoon ) draw routine test , learn body accept transplanted cell , check status disease . About 100 day transplant , bone marrow biopsy aspiration check status disease . This repeat 1 time year earlier , doctor think need . One ( 1 ) time year , x-rays bone body check status disease . The study staff also stay contact local doctor find disease come back check . This investigational study . Panobinostat melphalan FDA approve treatment MM . Busulfan FDA approve treatment leukemia . Gemcitabine FDA approve treatment lymphoma , breast cancer , lung cancer . The use study drug combination investigational . The study doctor explain study drug design work . Up 80 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>1 . Age 18 65 year . 2 . Refractory relapse myeloma , define one following : 2.1 . Treated firstline therapy include least 2 cycle lenalidomide , bortezomib thalidomide , one following : 2.1.1 . Less PR firstline therapy . 2.1.2 . Relapse 1st line therapy . 2.2 . Highrisk cytogenetics , define del ( 13q ) conventional cytogenetics , del ( 17p ) , ( 4 ; 14 ) , ( 14 ; 16 ) , ( 14 ; 20 ) 1q+ FISH . 2.3 . Relapse prior ASCT . 2.4 . Plasma cell leukemia . 2.5 . Soft tissue plasmacytoma . 3 . Adequate renal function , define serum creatinine &lt; /=1.8 mg/dL and/or estimate serum creatinine clearance &gt; /=50 ml/min . 4 . Adequate hepatic function , define SGOT and/or SGPT &lt; /=3 x upper limit normal ; serum bilirubin alkaline phosphatase &lt; /=2 x upper limit normal , unless prove due disease involvement . 5 . Adequate pulmonary function FEV1 , FVC DLCO &gt; /=50 % expect corrected hemoglobin and/or volume . 6 . Adequate cardiac function leave ventricular ejection fraction &gt; /=40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . Clinically euthyroid . Note : Patients permit receive thyroid hormone supplement treat underlying hypothyroidism . 8 . Zubrod performance status &lt; 2 . 9 . Negative BetaHCG test woman childbearing potential , define postmenopausal 12 month previous surgical sterilization . 10 . Availability &gt; /= 2.5 million CD34+ cells/kg previously apheresed . 11 . Ability provide write informed consent . 1 . Prior whole brain irradiation . 2 . Having receive radiation therapy head neck ( exclude eye ) , internal organ chest , abdomen pelvis month prior enrollment . 3 . Active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /=10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 5 . Active infection require parenteral antibiotic . 6 . Known positivity human immunodeficiency virus ( HIV ) . 7 . Autologous stemcell transplant previous six month . 8 . Needing valproic acid medical condition study within 5 day prior first panobinostat treatment . 9 . Impairment GI function GI disease may significantly alter absorption panobinostat . 10 . Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol . 11 . Impaired cardiac function clinically significant cardiac disease , include one following : 11.1 . History presence sustain ventricular tachyarrhythmia . ( Patients history atrial arrhythmia eligible discuss Novartis prior enrollment ) . 11.2 Any history ventricular fibrillation torsade de pointes . 11.3 . Bradycardia define HR &lt; 50 bpm . Patients pacemaker eligible HR &gt; /= 50 bpm . 11.4 . Screening ECG QTc &gt; 470 msec . 11.5 . Right bundle branch block + leave anterior hemiblock ( bifascicular block ) . 11.6 . Myocardial infarction unstable angina &lt; /= 12 month prior start study drug . 11.7 . Other clinically significant heart disease ( e.g. , CHF NY Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) . 12 . Have undergone major surgery &lt; /= 4 week prior start study drug recover side effect therapy . 13 . Prior malignancy last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) . 14 . Any significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff . 15 . Received targeted agent within 2 week within 5 halflives agent active metabolite ( whichever longer ) recover side effect therapy . 16 . Having receive immunotherapy chemotherapy within 2 week ; radiation therapy &gt; 30 % marrowbearing bone within &lt; /= 2 week prior start study treatment ; yet recover side effect therapy . 17 . Grade &gt; /= 3 nonhematological toxicity prior therapy resolve &lt; /= grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple myeloma ( MM )</keyword>
	<keyword>MM</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Kepivance</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>LBH589B</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Caphosol</keyword>
	<keyword>Glutamine</keyword>
	<keyword>Enterex</keyword>
	<keyword>Glutapak</keyword>
	<keyword>NutreStore</keyword>
	<keyword>Resource</keyword>
	<keyword>GlutaSolve</keyword>
	<keyword>Sympt-X</keyword>
</DOC>